Global Benign Prostatic Hyperplasia (BPH) Drugs Market 2017-2021

Benign prostatic hyperplasia (BPH) drugs market analysis

According to the benign prostatic hyperplasia drugs market analysis, the global BPH drugs market is expected to grow at a steady rate and post a CAGR of more than 7% during the forecast period. The growing demand for alpha-blockers will drive the prospects for the global BPH drugs market growth for the next four years.

The growing focus on improving the convenience and tolerability of drugs has resulted in the evolution of alpha-blockers therapy that is used to treat BPH by preventing the progression of disease or reversing the signs and symptoms. The growing need for relieving lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia drives the application of alpha-blockers because these blockers are highly effective and less expensive, which in turn, will boost the demand for BPH drugs. Also, to treat the symptomatic LUTS, the US Food and Drug Administration (FDA) has approved the use of terazosin, doxazosin, tamsulosin, and alfuzosin, which are the four long-acting alpha-1 blockers.

BPH drugs market trends

The advancements in early-stage diagnosis through new diagnostic methods is one of the key BPH drugs market trends that are responsible for the market’s growth. Some of the new diagnostic methods used to help in the early detection of BPH includes phi test, Progensa, 4Kscore test, TMPRSS2: ERG, and ConfirmMDX, which are proved to be more accurate than conventional methods such as prostate-specific antigen (PSA) blood test. The availability of such advanced diagnostic methods will further drive the patient pool and fuel the market’s growth.

Benign prostatic hyperplasia drugs market growth: Competitive landscape and key vendors

The BPH drugs market is characterized by the presence of many vendors, which makes the market fragmented in nature. These vendors are increasingly competing against each other based on factors such as aggressive pricing and new indications. With the growing medical need among patients suffering from BPH, several vendors are increasingly focusing on the development of effective BPH treatment solutions, which will widen the customer base and strengthen their geographical position in the market. Furthermore, many vendors are also coming up with better products by indulging themselves in continuous innovative activities through optimal resource allocation and robust research and developmental activities.

Key vendors in the BPH drugs market

• Astellas Pharma
• Eli Lilly
• GlaxoSmithKline
• Sanofi

BPH drugs market segmentation by MOA

• Alpha-blocker
• Phosphodiesterase type-5 inhibitors
• 5-alpha-Reductase inhibitors

The BPH alpha-blockers drugs segment dominated the BPH drugs market during 2016 and will continue to dominate the market from 2017 to 2021. This segment includes several alpha-blockers such as alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax), and terazosin (Hytrin). The availability of a wide range of drugs such as Astellas Pharma's Harnal and Omnic, Sanofi's Xatral, and Recordati's Urorec is the major factor that ensures its market dominance for the next few years.

BPH drugs market overview based on geography

• Americas
• APAC
• EMEA

The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global benign prostatic hyperplasia (BPH) drugs market?
• What are the key market trends impacting the growth of the global benign prostatic hyperplasia (BPH) drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global benign prostatic hyperplasia (BPH) drugs market?
• What are the market opportunities and threats faced by the vendors in the global benign prostatic hyperplasia (BPH) drugs market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global benign prostatic hyperplasia (BPH) drugs market?

Technavio also offers customization on reports based on specific client requirement.